Related Experiment Video
Updated: Dec 15, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19
Matthew R Davis1, Erin K McCreary2, Jason M Pogue3
1Department of Clinical Pharmacy, University of California Los Angeles Ronald Reagan Medical Center, Los Angeles, CA, USA. MRDavis@mednet.ucla.edu.
Abstract:
Remdesivir is a nucleoside antiviral recently studied in several randomized trials for treatment of COVID-19. The available observational and prospective data are conflicting, requiring clinicians to critically evaluate and reconcile results to determine patient populations that may optimally benefit from remdesivir therapy, especially while drug supply is scarce. In this review, we analyze pertinent clinical remdesivir data for patients with COVID-19 from January 1, 2020, through May 31, 2020.
More Related Videos
Related Concept Videos
Subviral Agents
Therapeutic Drug Monitoring: Overview and Classification
Drug Therapy
Antianxiety Medications
Retrovirus Life Cycles
Myocarditis III: Medical Management
Therapeutic Drug Monitoring: Affecting Factors

